在患有心血管风险因素的人群中,埃斯特/德罗斯皮伦的安全性
Mitchell D Creinin1, Jean Michel Foidart2, Kristina Gemzell-Danielsson3
1Department of Obstetrics and Gynecology, University of California, Davis, Sacramento, CA, United States.
Contraception
|March 2, 2025
概括
埃斯特/德罗斯皮伦在具有风险因素的女性中显示出出色的心血管安全性. 对不良事件的停药率相似,由于高血压而停药的人很少.
科学领域:
- 生殖健康 生殖健康
- 心血管安全心血管安全
- 药理学 药理学是指药理学的学科.
背景情况:
- 联合口服避孕药 (COCs) 广泛用于避孕.
- 对于COC使用者来说,心血管安全是关键考虑因素,特别是那些有风险因素的人.
- 埃斯特醇/德罗斯皮伦是一种新型的COC配方.
研究的目的:
- 为了评估15毫克埃斯特/drospirenone 3毫克在患有心血管风险因素的使用者的心血管安全性.
- 为了比较患有心血管风险因素和没有心血管风险因素的参与者之间的心血管事件导致的不良事件率和中止率.
主要方法:
- 两个开放标签,第三阶段避孕药试验的二次分析.
- 参与者 (16-50岁) 使用埃斯特罗尔/德罗斯皮雷诺多达13个周期.
- 在有心血管风险因素和没有心血管风险因素的参与者中比较不良事件率和中止率.
主要成果:
- 1410名 (41.3%) 参与者有一种或多种心血管风险因素.
- 两组之间因不良事件而停止治疗没有差异.
- 只有三名 (0.09%) 参与者因高血压而停止治疗,所有参与者均具有高正常基线血压和额外的危险因素.
结论:
- 埃斯特/德罗斯皮伦在患有正常和高正常血压的女性中表现出极好的心血管耐受性,包括患有心血管风险因素的女性.
- 高血压的低率表明,在寻求避孕的高血压女性中可能进行试验.
相关概念视频
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K
01:12Relative Risk
105
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
105
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
454
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
454
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
111
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
111
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
142
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
142
01:23Antihypertensive Drugs: Vasodilators
455
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
455